Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Inclusion Criteria:

- Participant must have a body mass index (BMI: weight in kg divided by the square of
height in meters) of 18.0 to 32.0 kilogram per meter (kg/m^2), extremes included, and
a body weight not less than 50.0 kg

- Participant must have a blood pressure (supine after at least 5 minutes rest) between
90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90
mmHg diastolic. If blood pressure is out of range, up to 2 repeated assessments are
permitted. Participants with a normal value at retest may be included

- Participant must have a normal 12-lead Electrocardiogram [ECG] (based on the mean
value of triplicate ECG parameters) consistent with normal cardiac conduction and
function at screening, including:a) normal sinus rhythm (heart rate (HR) between 60
and 90 beats per minute [bpm], extremes included); b) QT interval corrected for heart
rate according to Fridericia's formula (QTcF) less than or equal to <=450 milliseconds
(ms) for male participants and <=470 ms for female participants; c) QRS interval <=110
ms; d) PR interval <=200 ms; e) Electrocardiogram (ECG) morphology consistent with
healthy cardiac conduction and function. Any evidence of heart block is exclusionary.
Any evidence of left or right bundle branch block is exclusionary

- Female participant must have a negative highly sensitive urine or serum pregnancy test
at Day -1

Exclusion Criteria:

- Participant with a past history of: a) Heart arrhythmias (example, extrasystolic
rhythms or tachycardia at rest). Isolated extrasystolic beats are not exclusionary; b)
Risk factors associated with Torsade de Pointes such as hypokalemia; c) Family history
of short/long QT syndrome; d) Sudden unexplained death (including sudden infant death
syndrome) in a first degree relative (that is, sibling, offspring, or biological
parent)

- Participant has known allergies, hypersensitivity, or intolerance to odalasvir (ODV),
AL-335, simeprevir (SMV), lansoprazole, or omeprazole, or their excipients

- Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C
antibody (anti-HCV) positive, or other clinically active liver disease, or tests
positive for HBsAg or anti-HCV at screening

- Participant has a history of human immunodeficiency virus (HIV-1) or -2 infection
positive, or tests positive for HIV-1 or -2 at screening

- Participant has previously been dosed with SMV, ODV, or AL-335 in more than 3
single-dose studies or in a multiple dose study with SMV, ODV, or AL-335